Cargando…

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer

SIMPLE SUMMARY: New blood vessel formation (angiogenesis) has a crucial role in tumour growth and spread. Bevacizumab is an anticancer therapy that targets angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) and is approved for the treatment of metastatic breast cancer. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Vega, José Manuel, Álvarez, Isabel, Antón, Antonio, Illarramendi, José Juan, Llombart, Antonio, Boni, Valentina, García-Velloso, María José, Martí-Climent, Josep María, Pina, Luis, García-Foncillas, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307791/ https://www.ncbi.nlm.nih.gov/pubmed/34298725 http://dx.doi.org/10.3390/cancers13143511

Ejemplares similares

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
por: Garcia-Casado, Zaida, et al.
Publicado: (2010)

MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?
por: Zarate, Ruth, et al.
Publicado: (2012)

Effective dose estimation for oncological and neurological PET/CT procedures
por: Martí-Climent, Josep M., et al.
Publicado: (2017)

PET Tracers for Clinical Imaging of Breast Cancer
por: Peñuelas, Iván, et al.
Publicado: (2012)

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
por: García-Alfonso, Pilar, et al.
Publicado: (2015)

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
por: Calleja, Miguel Angel, et al.
Publicado: (2023)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2010)

Primary bone lymphoma of the mandible and thyroid incidentaloma identified by (18)FDG PET/CT: a case report
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2009)

Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases
por: Alcaide, Julia, et al.
Publicado: (2016)

Bevacizumab or laser for aggressive posterior retinopathy of prematurity
por: Blair, Michael, et al.
Publicado: (2018)

Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer
por: Gómez del Pulgar, Teresa, et al.
Publicado: (2016)

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2021)

Socio-Economic Development and Mental Health: Case Study of the Spanish Region of Aragon (2010–20)
por: Bentué-Martínez, Carmen, et al.
Publicado: (2022)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021)

Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity
por: Batista, Marta Vaz, et al.
Publicado: (2023)

Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
por: Taboada, Alvaro Gregorio Morales, et al.
Publicado: (2021)

High-Risk Clinicopathological and Genetic Features and Outcomes in Patients Receiving Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer
por: del Carmen, Sofía, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
por: de Melo Gagliato, Debora, et al.
Publicado: (2020)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

Bevacizumab in ovarian cancer: A critical review of phase III studies
por: Rossi, Luigi, et al.
Publicado: (2016)

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
por: Lindholm, Evita Maria, et al.
Publicado: (2019)

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
por: Starlinger, P, et al.
Publicado: (2012)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Honrubia-Peris, Beatriz, et al.
Publicado: (2021)

Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity
por: Pérez, Jesús Chamorro, et al.
Publicado: (2023)

Correction to: Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity
por: Pérez, Jesús Chamorro, et al.
Publicado: (2023)

Physiological Studies of Glutamine Synthetases I and III from Synechococcus sp. WH7803 Reveal Differential Regulation
por: Domínguez-Martín, María Agustina, et al.
Publicado: (2016)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Grieving for Job Loss and Its Relation to the Employability of Older Jobseekers
por: Climent-Rodríguez, José Antonio, et al.
Publicado: (2019)

Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?
por: Cortes-Guiral, Delia, et al.
Publicado: (2017)

Probabilidad y Estadística /
por: Climent Hernández, José Antonio
Publicado: (2021)

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
por: Márquez-Rodas, Iván, et al.
Publicado: (2017)

Neoadjuvant Trabectedin plus Radiotherapy in High-Grade Sarcoma of the Leg: A Case Report
por: Loureiro da Silva, António José, et al.
Publicado: (2018)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis
por: Junker, Philip, et al.
Publicado: (2018)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
por: Sabatier, Renaud, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7c1aojq512risabhu0st253uqh